Mark Murnin, DO
Internal Medicine · Hamlin, PANPI 1528043213
Payments from drug & device makers
Across 169 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$651
- Pfizer$358
- Novo Nordisk$351
- AstraZeneca$202
- E.r. Squibb & Sons, L.L.C.$182
- Astellas Pharma US Inc$164
- plus $899 from 22 others
What the payments were for
- Food & beverage$2,805100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 37 | $651 |
| Pfizer | 26 | $358 |
| Novo Nordisk | 21 | $351 |
| AstraZeneca(2 entities) | 12 | $202 |
| E.r. Squibb & Sons, L.L.C. | 12 | $182 |
| Astellas Pharma US Inc | 8 | $164 |
| Amgen | 8 | $130 |
| Lilly USA, LLC | 7 | $114 |
| Bayer | 4 | $76 |
| Johnson & Johnson | 5 | $72 |
| Sunovion Pharmaceuticals Inc. | 3 | $68 |
| Exact Sciences | 3 | $58 |
| Radius Health, Inc. | 3 | $57 |
| Abbott | 3 | $54 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Verona Pharma, Inc. | 1 | $27 |
| Novartis | 1 | $22 |
| Prescient Lab Services, LLC | 1 | $18 |
| Merck | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| AbbVie | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| CTI Biopharma Corp. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$2,805 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $180,902 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $80,997 |
| OzempicSemaglutide | 49 | $67,068 |
| JanuviaSitagliptin Phosphate | 52 | $53,273 |
| JardianceEmpagliflozin | 52 | $48,822 |
| RybelsusSemaglutide | 36 | $46,660 |
| XareltoRivaroxaban | 31 | $26,870 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $26,551 |
| MyrbetriqMirabegron | 26 | $23,956 |
| FarxigaDapagliflozin Propanediol | 15 | $18,917 |
| TradjentaLinagliptin | 28 | $18,609 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $18,376 |
| MounjaroTirzepatide | 12 | $14,191 |
| TrulicityDulaglutide | 12 | $10,000 |
| Atorvastatin Calcium | 765 | $9,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $358 | $180,902176 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $651 | $125,924163 claims |
| Novo NordiskOzempic, Rybelsus | $351 | $113,72885 claims |
| MerckJanuvia | $18 | $53,27352 claims |
| Johnson & JohnsonXarelto, Invokana | $72 | $33,89446 claims |
| Lilly USA, LLCMounjaro, Trulicity | $114 | $24,19124 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $23,95626 claims |
| AstraZenecaFarxiga | $202 | $18,91715 claims |
| AbbVieSynthroid | $17 | $1,97059 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Hamlin
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.